protein D (SP-D) is an important innate immune defense molecule that mediates clearance of pathogens and modulates the inflammatory response. Moreover, SP-D is involved in lipid homeostasis, and pulmonary accumulation of phospholipids has previously been observed in SP-D-deficient (SpdϪ/Ϫ) mice. Atherogenesis involves both inflammation and lipid deposition, and we investigated the role of SP-D in the development of atherosclerosis. SP-D synthesis was localized to vascular endothelial cells. Atherosclerotic lesion areas were 5.6-fold smaller in the aortic roots in SpdϪ/Ϫ mice compared with wild-type C57BL/6N mice on an atherogenic diet. HDL cholesterol (HDL-C) was significantly elevated in SpdϪ/Ϫ mice. Treatment of SpdϪ/Ϫ mice with a recombinant fragment of human SP-D resulted in decreases of HDL-C (21%) as well as total cholesterol (26%), and LDL cholesterol (28%). Plasma TNF-␣ was reduced in SpdϪ/Ϫ mice (45% difference). SP-D was proatherogenic in the mouse model used. The effect is likely to be due to the observed disturbances of plasma lipid metabolism and alteration of the inflammatory process, which underlie the reduced susceptibility to atherosclerosis in SpdϪ/Ϫ mice. atherosclerosis; experimental animals; high-density lipoprotein; tumor necrosis factor-␣;
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SURFACTANT PROTEIN D (SP-D) is a member of the collectin family of collagen-like lectins (12) . The protein is mainly studied in relation to pulmonary immune defense, although it is present in various mucosal surfaces (25) and in the circulation (9a, 21, 38a) . SP-D is a molecule with several known functions. It is a pattern recognition molecule binding carbohydrate and lipid moieties presented on the surface of pathogenic microorganisms and apoptotic cells. The binding initiates various effector mechanisms, such as alteration of membrane permeability or activation of phagocytes, which may enable the elimination of the bound material. SP-D, moreover, shows a strong chemotactic effect on inflammatory cells, including granulocytes, and macrophages, and SP-D-deficient (SpdϪ/Ϫ) mice have increased levels of proinflammatory cytokines, metalloproteinases, and oxidant species in the lung (40 -42) .
SpdϪ/Ϫ mice accumulate phospholipid in the alveolar space. Alveolar macrophages are found in increased numbers, and many macrophages are multinucleated and foamy in appearance because of lipid engorgement (2, 13) .
Atherosclerosis is a complex disease involving many cell types and biochemical pathways. Current understanding of the pathogenesis has emphasis on the importance of inflammatory mechanisms, which couple dyslipidemia to atheroma formation. Specific gene products identified by descriptive studies have been causally related to inflammation during atherogenesis with the use of genetically altered mice, especially with emphasis on mononuclear phagocyte biology (23) . The welldocumented presence of SP-D in the circulation, and the multiple effects of the protein in regulation of lipid and inflammation homeostasis, led us to investigate whether SP-D could affect systemic lipid homeostasis and inflammation and alter susceptibility to atherosclerosis in a mouse model.
MATERIALS AND METHODS
Cell culture, RNA purification, and RT-PCR. Primary human umbilical artery endothelial cell (HUAEC) cultures were isolated from normal human umbilical cords by collagenase treatment. The cords were obtained from the Department of Obstetrics and Gynecology, Odense University Hospital. The Scientific Ethics Committee for Vejle and Fyns Amter approved the study. HUAEC cultures were seeded on gelatin-coated tissue culture plastic, and the cultures were maintained in endothelial growth medium EGM-2 (Clonetics, Walkersville, MD) and kept at 37°C, 95% humidity, and 5% CO 2. Cells were detached for passaging with trypsin-EDTA solution for endothelial cultures (Sigma-Aldrich, Steinheim, Germany) and used until passage 7. Total RNA purification was performed with an Rneasy Mini kit (Qiagen, Hilden, Germany). Veins and arteries were dissected from normal human umbilical cords and stored in RNAlater (Ambion, Austin, TX) until total RNA purification by Tri Reagent (Sigma-Aldrich). First-strand cDNA was generated (Superscript II, Invitrogen, Carlsbad, CA), and PCR was performed with the following primers spanning exon-exon splice junctions and amplifying the neck and carbohydrate recognition domain (CRD) region: SP-D f1, 5Ј-ATGTTGCTTCTCTGAGG-3, SP-D r1, 5Ј-TCAGAACTCGCAG-ACCA-3Ј (43 cycles); actin rew2 5Ј-AGTCCGCCTAGAAG-CATTTG-3Ј and actin forw, 5Ј-ATGCAGAAGGAGATCACTGC-3Ј (24 cycles). Annealing temperature was 55°C. The reaction mixtures were run on a 1% agarose gel, and bands of the correct size were isolated for direct sequencing. No bands were detectable in blank reactions. Mouse thoracic aorta was frozen in liquid nitrogen after dissection, and RT-PCR was performed as previously described (26) .
Western blotting and immunohistochemistry. Western blotting of tissue homogenates or lysed cell culture was performed essentially as described by Madsen et al. (25) on 8 -25% (wt/vol) polyacrylamide gradient gels. Primary anti-SP-D antibody was mouse monoclonal antibody Hyb245-2 (1 g/ml). Secondary antibodies were alkaline phosphatase-coupled rabbit anti-mouse Ig (DakoCytomation, Copenhagen, Denmark).
Cell cytospins were acetone fixed. Formaldehyde-fixed paraffinembedded tissue sections were mounted on slides, dried at 60°C, deparaffinized, hydrated, and processed as previously described (16) . Monoclonal antibodies directed against SP-D (Hyb245-1) were produced and characterized as previously described (25) . Normal human tissues and atherosclerotic tissue were from the tissue bank at the Department of Pathology, Odense University Hospital. Monoclonal anti-CD34 and anti-CD31 antibodies (DakoCytomation) were used as positive controls for endothelial cells. A biotin-streptavidin immunoperoxidase technique was used on paraffin sections. Enhanced epitope retrieval was obtained by microwave heat treatment of the specimen. Briefly, paraffin sections were pretreated in 10 mM Tris with 0.5 mM EGTA, pH 9.0 before microwave treatment and immunostaining. The specificity of immunostaining was verified by replacing the primary antibodies with an isotype monoclonal antibody.
Purification of human SP-D. Human SP-D was isolated from amniotic fluid by maltose-agarose (Sigma-Aldrich) affinity chromatography (Amersham Biosciences) as previously described (39) .
Mouse feeding study. Homozygous SpdϪ/Ϫ mice (2) were backcrossed Ͼ10 times with the C57BL/6N strain. The C57BL/6N (wild type) mice used in this study were obtained from Charles River Laboratories (Sulzfeld, Germany). The National Animal Ethics Committee approved the study and all procedures. The newborn mice had free access to regular chow (Altromin 1314, Brogården Aps, Gentofte, Denmark). The lighting schedule was 12 h of light and 12 h of dark. Mice were fed and given water ad libitum. A total of 67 5-wk-old wild-type and SpdϪ/Ϫ female mice were fed an atherogenic diet for 36 wk (TD 88051, Harlan, Kreuzelweg, Netherlands) containing 15.8% (wt/wt) fat, 1.25% (wt/wt) cholesterol, and 0.5% (wt/wt) sodium cholate as previously described (14, 29) . Some mice were killed during the feeding study to follow the development of aortic lesions. One SpdϪ/Ϫ mouse died during the time span of the experiment because of failure to thrive. The numbers of mice used for analyses are shown in Table 1 . Blood samples were collected by retroorbital puncture unless otherwise stated.
Plasma lipids. Plasma lipids were measured with a Cobas Mira instrument (Triolab A/S, Copenhagen, Denmark). Triglycerides (TG), total cholesterol (TC), LDL cholesterol (LDL-C), and HDL cholesterol (HDL-C) were measured with ABX Diagnostics reagents. All assays were performed according to the manufacturer's directions (Triolab A/S). Plasma samples were used diluted zero-to threefold in 0.9% (wt/vol) sodium chloride.
Plasma cytokines. The cytokine contents in plasma from mice after 36 wk of diet was measured by means of the Mouse Th1/Th2 cytokine cytometric bead array (CBA) kit (Becton-Dickinson, Copenhagen, Denmark), using a FACSCalibur flow cytometer (Becton-Dickinson) and the corresponding CBA analysis software (Becton-Dickinson). The kit contains five populations of beads that have been coated with capture antibodies for TNF-␣, INF-␥, IL-2, IL-4, and IL-5, respectively. The assay was performed according to the manufacturer's directions. IL-4 measurements were excluded from analysis because 16 of 37 measurements fell below the detection limit. The numbers of mice used for cytokine analyses are shown in Table 1 .
Aortic lesions. For aortic lesion analysis, nonfasting mice were anesthetized with 100 mg/kg pentobarbital (Den Kgl. Veterinaer og Landbrohøjskoles apotek, Copenhagen, Denmark), exsanguinated, and perfusion fixed, and the pathoanatomy was analyzed as described previously (1) . The amount of atherosclerosis in the aortic root was expressed as 1 mean plaque area/animal (mean of 3 sections) measured in a blinded fashion by one person (G. L. Sorensen).
Half-life of recombinant fragment human SP-D in SpdϪ/Ϫ mouse plasma. Eight 3-to 4-mo-old SpdϪ/Ϫ mice were included in this study (Table 1) . Each mouse received one bolus of 90 g of recombinant fragment human SP-D (rfhSP-D) in 250 l of sterile isotonic sodium chloride solution injected in the tail vein. The fragment was a 60-kDa homotrimer of recombinant SP-D, composed of eight GlyXaa-Yaa repeats from the collagen region, the ␣-helical coiled-coil neck region, and the CRD, and was expressed in Escherichia coli as previously described (24) . The endotoxin level in the rfhSP-D infusion was Ͻ0.2 EU/ml measured by the Limulus amebocyte lysate QCL-1000 assay (BioWhittaker, Walkersville, MD). The rfhSP-D concentration was measured by ELISA technique as previously described (21) , and the half-life was estimated. Plasma samples were frozen before the immunoassay was performed.
Treatment of mice with rfhSP-D. Five-week-old SpdϪ/Ϫ female mice were fed the atherogenic diet for 5 days. One group of mice received 9 g rfhSP-D/280 l sterile isotonic sodium chloride by daily tail vein infusions. The endotoxin level in the rfhSP-D infusion was Ͻ0.02 EU/ml. Another group received 9 g human serum albumin (HSA)/280 l sodium chloride solution daily. Plasma lipids and rfhSP-D concentrations were measured as described above (Table  1 ). Blood samples from untreated mice were collected by retroorbital puncture, whereas blood samples from HSA-or rfhSP-D-treated mice were collected by heart puncture in anesthetized mice. The serum albumin was prepared for human infusion under endotoxin-free conditions and kindly provided by Claus Koch (State Serum Institute, Copenhagen, Denmark). The two groups of mice were killed by anesthesia (as described above) and exsanguination.
Statistics. Differences between groups of data were evaluated by the nonparametric Mann-Whitney U-test. A value of P Ͻ 0.05 was regarded as significant. Relationships between plaque areas and mouse HDL-C were analyzed by linear regression. All statistical analyses were performed with Intercooled Stata version 7.0.
RESULTS

SP-D expression by endothelial cells. SP-D was previously
localized to cells in a variety of tissues by the specific monoclonal antibody Hyb245-1 (25) . This antibody also detects Values are numbers of mice used for measurements in the atherosclerosis study, the recombinant fragment human surfaciant protein D (rfhSP-D) halflife study, and the rfhSP-D treatment study. Horizontal rows show numbers of different measurements from the same group of mice. In some studies there was not sufficient plasma for all lipid or cytokine analyses, and the number of measurements thus varies with the type of analysis. F, female; M, male; HSA, human serum albumin.
SP-D in vascular endothelial cells in all tissues examined. Hyb245-1 reacted with endothelial cells in arteries and veins in microvasculature as well as in macrovasculature and in highendothelium venules. SP-D immunoreactivity to endothelial cells is shown for selected tissues in Fig. 1 .
Primary HUAEC cell lines were established to study SP-D expression. HUAEC cytospin preparations reacted with Hyb245-1. Staining was not detected with primary isotype control antibodies (data not shown). Immunostaining was highly granular, indicating that the intracellular localization of SP-D is vesicular. The primary endothelial cells costained for endothelial markers CD31 and CD34 (Fig. 2, A-E) . In the seventh to eighth passage the endothelial cell cytospin preparations reacted with Hyb245-1, although the immunoreactivity was significantly diminished in parallel with the endothelial cell marker CD31 (data not shown). The cultures sustained the expression of the endothelial cell marker CD34 throughout all investigated passages. The loss of SP-D protein expression was suspected to be due to cell culture senescence.
Whole arteries were isolated from human umbilical cords. RT-PCR analysis amplifying the SP-D neck/CRD region and successive sequencing of the PCR product demonstrated the synthesis of SP-D polyadenylated RNA in the vascular tissue (Fig. 2F) . The corresponding fragment could also be amplified from HUAEC cultures. The SP-D mRNA expression was accelerated with increasing seeding density of the cell culture. The PCR reaction was normalized to ␤-actin mRNA expression (Fig. 2G) . RT-PCR analysis amplifying the full-length SP-D transcript showed mRNA from HUAEC culture to be identical in size to that from the lung, and the sequence obtained from the PCR product was identical to the known sequence obtained from lung mRNA (data not shown).
Western blotting of lysates prepared from HUAEC culture demonstrated that the monoclonal anti-human SP-D antibody Hyb245-2 recognized endothelial SP-D protein. The fully reduced endothelial protein showed slightly altered mobility in the SDS-PAGE compared with the 43-kDa SP-D polypeptide monomers of SP-D protein purified from amniotic fluid, and no higher oligomeric forms were detected in the unreduced sample (Fig. 2H) . A band appeared in the blot from HUAEC, suggesting proteolytic cleavage of the cellular SP-D possibly preventing oligomerization. Corresponding Hyb245-2 reactiv- ity was observed in lysates of human umbilical arterial and vein tissues (data not shown).
RT-PCR analysis amplifying the mouse SP-D neck/CRD mRNA and successive sequencing of the PCR product demonstrated the synthesis of SP-D polyadenylated RNA in the vascular tissue (Fig. 2I) . The PCR reaction was normalized to mouse transferrin receptor mRNA expression. Spd expression in the aorta was detectable after 36 PCR cycles. In contrast, no expression product appeared in the heart sample after 40 PCR cycles. The same RT-PCR protocol previously demonstrated highly specific patterns of mouse SP-D expression (26) . The main sites of synthesis were in tissues like lung, uterus, and salivary gland, whereas there was no detectable expression in tissues like heart and spleen.
SpdϪ/Ϫ mice are protected against development of atherosclerotic lesions in aortic root. C57BL/6 female mice are known to develop atherosclerotic lesions in the aortic root when kept on an atherogenic diet (14) . In contrast, male mice are not susceptible to diet-induced atherosclerosis. SpdϪ/Ϫ female mice and, for comparison, the corresponding C57BL/6N female mice were fed the diet, and the formation of atherosclerotic lesions in the aortic root was followed. Groups of four mice were killed and evaluated after 12 and 24 wk, but none or only small foam cell lesions were found. After 36 wk the remaining mice were killed and the aortic roots examined. No structural remodeling (nonlesion) in the aortic root was apparent in SpdϪ/Ϫ mice. Lesion areas are shown in Fig. 3 . A significant difference was found between SpdϪ/Ϫ mice and wild-type mice (Fig. 3A) , with median lesion areas in the wild-type mice exceeding the SpdϪ/Ϫ mice by 5.6-fold. Lesions in SpdϪ/Ϫ mice consisted only of foam cells (fatty streaks), whereas many of the lesions in wild-type mice were mature atherosclerotic plaques with extracellular matrix containing lipid (cholesterol clefts) and collagen (Fig. 3, B-E) .
Mean and maximal atherosclerotic lesions are shown in Fig.  3, F-I , for SpdϪ/Ϫ mice and wild-type mice. Lung sections obtained from the same animals are shown in Fig. 3 , J-M. The pulmonary phenotype of SpdϪ/Ϫ mice was previously described with emphysema (2, 13). The wild-type mice showed normal lung morphology, whereas the SpdϪ/Ϫ mice showed alveolar infiltrations with lymphocytes and foam cells. The SpdϪ/Ϫ mice in our experiment were thus prone to emphysema development but partly protected from atherosclerosis.
The atherogenic diet was well tolerated by both SpdϪ/Ϫ mice and wild-type mice, and both groups gained weight at a faster rate than on a normal chow (data not shown).
Plasma lipids are altered in SpdϪ/Ϫ mice. Significantly higher levels of HDL-C and TG were observed in SpdϪ/Ϫ female mice compared with wild-type mice (Fig. 4) , measured at individual time points throughout the study or as the integrated area under the curve (AUC). No differences were observed or sustained in TC or LDL-C between the genotypes. HDL-C levels were increased on average 18% in SpdϪ/Ϫ mice compared with wild-type mice, comparing genotype AUC. No initial difference was detected between TG levels. The dietinduced depression of TG was less pronounced in the SpdϪ/Ϫ animals, with an average difference of 27% between the genotype AUCs. In addition, plasma lipids were measured in parallel experiments also using male mice and regular chow. These experiments indicated that the HDL-C fraction is most affected in female SpdϪ/Ϫ mice (data not shown). HDL-C levels were negatively associated to lesion sizes in the experiment. Linear regression was applied to estimate the relationship and indicated that a drop of 50,999 m 2 in lesion size was associated with a rise of 1 mM HDL-C (P ϭ 0.01; R 2 ϭ 0.33).
Recombinant SP-D reduces plasma lipid concentrations. Eight mice received 90 g of rfhSP-D injected intravenously.
Blood samples were drawn over a period of 50 h, and ELISA technique was used to measure the retrieved rfhSP-D concentrations. As predicted, the assay did not give any signal from the plasma from the untreated SpdϪ/Ϫ mice. The mean plasma concentrations obtained are shown in Fig. 5A . The initial mean concentration measured after 1 h was ϳ8 g/ml plasma and reflected that redistribution had occurred at this time point. The declining plasma concentration corresponded to a mean halflife of 62 h.
Next, groups of SpdϪ/Ϫ and wild-type female mice received daily intravenous infusions of 9 g of human recombinant rfhSP-D over 5 days. Corresponding control groups of female mice received HSA. All mice received the atherogenic diet during the five treatment days. Plasma rfhSP-D concentrations were measured on a daily basis in two of the rfhSP-D-treated mice thereafter. rfhSP-D concentrations oscillated around an average of 2,513 ng rfhSP-D/ml plasma. TG and HDL-C levels were depressed by the 5 days of atherogenic diet. In contrast, LDL-C and TC were increased by the atherogenic diet. The relative difference in HDL-C, TC, and LDL-C levels seen between SpdϪ/Ϫ mice receiving rfhSP-D and those receiving albumin was a lowering of the levels by 21%, 26%, and 28%, respectively (Fig. 5B, right) .
SpdϪ/Ϫ mice on high-fat diet have decreased levels of serum TNF-␣. Plasma cytokines were measured in blood collected after 36 wk of atherogenic diet (Fig. 6) . Average TNF-␣ levels were significantly (P ϭ 0.0001) decreased from 77.3 pg/ml in wild-type mice to 42.2 pg/ml in SpdϪ/Ϫ mice (45% difference). No significant differences were measured between SpdϪ/Ϫ mice and wild-type mice in INF-␥, IL-2, and IL-5 levels.
DISCUSSION
Monogenic causes of atherosclerosis are rare and cannot account for the prevalence of the disease. Recent studies in genetically deficient mice indicate that numerous components of both the innate and the adaptive immune system can act as modifiers of atherosclerosis (23, 38) . Here we document transcription of the Spd gene in vascular endothelial cells and demonstrate that SP-D increases susceptibility to atherosclerosis in mice.
Serum SP-D has been regarded as a spillover from the pulmonary compartment and has been studied as a marker of several pulmonary diseases (18, 21) . We have now demonstrated that SP-D is synthesized in vascular endothelial cells in both mice and humans. The mRNA expression was relatively low in both species but was inducible in cell culture. SP-D protein was located to human endothelial cells in all tissues, including atherosclerotic lesions. The endothelial cell SP-D protein was apparently proteolytically cleaved or alternatively modified compared with the purified SP-D from amnion fluid, and no covalently linked trimeric forms were detected by Western blotting. Specific functions of a putative endothelial SP-D form may be expected and possibly could explain the apparent proinflammatory effect of SP-D in the vasculature of the mice in this study. Nevertheless, it remains to be explored whether SP-D of endothelial origin represents a physiologically active form present outside the endothelial cell and whether the putative alternative form of SP-D is restricted to umbilical endothelial cells. In this regard, serum SP-D was previously demonstrated to form higher oligomers according to individual Spd genotype variations (20) .
Inbred mouse strains have become a useful tool for identifying genetic factors contributing to atherosclerosis. It is possible to induce atherosclerosis in certain strains with cholesterol-and cholic acid-rich atherogenic diets. This model is nevertheless limited by incomplete penetration of the atherosclerotic phenotype (29, 30) . The antiatherogenic effect of a single gene may, on the other hand, be concealed in genetically modified mouse models that develop robust atherosclerosis (36) . We chose the diet-induced atherosclerosis model and observed a dramatic difference between SpdϪ/Ϫ mice and wild-type mice, which is comparable to the effect observed with the macrophage colony-stimulating factor-deficient apoEϪ/Ϫ mice (8) . Lesion sizes were small in the SpdϪ/Ϫ Fig. 4 . Plasma lipid concentration curves for female mice given atherogenic diet over 36 wk. E, SpdϪ/Ϫ; ϫ, wild-type; HDL-C, HDL cholesterol; TG, triglycerides; TC, total cholesterol; LDL-C, LDL cholesterol; PAUC, P value obtained by comparing the areas under the curves; NS, nonsignificant. Error bars indicate SE. Significant difference between the genotypes: *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. mice, which only developed foam cell lesions. In contrast, many of the wild-type mice had developed mature atherosclerosis with abundant extracellular matrix containing cholesterol clefts and collagen. The variation in lesion size in the wild-type mice corresponded to the variation observed in apoEϪ/Ϫ mice fed a regular chow (1) .
In vivo studies previously suggested that multiple SP-D functions are mediated through the lectin domain and showed that rfhSP-D has therapeutic effects in mice (24) . In our experiments, HDL-C and TG were significantly increased in SpdϪ/Ϫ mice and 5 days of rfhSP-D treatment resulted in lowered HDL-C, LDL-C, and TC. The apparent SP-D-mediated regulation of multiple lipid fractions indicates that a general factor in lipid transport or metabolism is influenced. The effective dose of rfhSP-D in the treated animals approximated 2.5 g/ml and was considered close to physiological levels as the SP-D serum level in humans is estimated at a median value of 743 ng/ml, with the normal concentration spectrum ranging from 158 to 3,711 ng/ml (21, 38a). However, the physiological level of serum SP-D in mice with chronic inflammation is measured to approximately 100 ng/ml (9a), and differences in both structure and concentration between the rfhSP-D used in the current study and serum SP-D in wild-type mice should be taken into consideration when interpreting lipid fractions affected by SP-D.
Direct association between lesion size and HDL-C and the antiatherogenic properties of mouse HDL are controversial (30, 37) , and the difference in HDL-C levels between SpdϪ/Ϫ mice and wild-type mice in our study was rather limited compared with similar studies (14, 30) . Nevertheless, HDL-C was directly associated to lesion size in our study, suggesting that the HDL-C level indeed plays a role in determining the reduced lesion susceptibility in SpdϪ/Ϫ mice. Quantitative trait loci analyses have demonstrated that the extent of atherosclerosis and HDL-C levels are determined by the genetic background (7, 14) , and Spd may be suggested as a common susceptibility gene for lesion size and HDL-C levels. Extrapolation from results obtained in mouse models to human physiology is complicated by multiple differences between the species (28, 31) . Nevertheless, in a human study including 757 subjects we observed parallel inverse associations between SP-D and HDL-C resulting in a ␤-coefficient of Ϫ105 ng/ml SP-D per 1 mM HDL-C in healthy women (P ϭ 0.02, R 2 ϭ 0.12; G. L. Sorensen and U. Holmskov, unpublished data).
Th1, the most prevalent type of CD4ϩ cell, induces macrophage activation and promotes inflammation by secretion of INF-␥, IL-2, and TNF-␣. However, Th2 cells suppress inflammation and dampen macrophage activity via several different anti-inflammatory cytokines like IL-4 and IL-5. In a recent study, apoEϪ/Ϫ mice were treated with an inhibitor of the Th1 differentiation pathway (pentoxifyllin) for 12 wk and the animals presented with reduced size of atherosclerotic lesions by 60% compared with controls (19) . In the present study representative Th1 and Th2 cytokines were measured at the study end point to evaluate whether the inflammatory component of atherosclerosis was disturbed in the SpdϪ/Ϫ mice.
The proinflammatory Th1 cytokine TNF-␣ in plasma was significantly lower in SpdϪ/Ϫ mice compared with wild-type mice. The measured TNF-␣ levels were raised two-to threefold above background but did not compare to the induction measured in LPS-treated mice in thousands of picograms pr milliliter. The measured difference in TNF-␣ levels may represent a reduced Th1 response in SpdϪ/Ϫ mice in accordance with studies of allergen-induced pulmonary hypersensitivity in which treatment with rfhSP-D shifted the allergic response into a Th1 response (24) .
TNF-␣ is produced primarily from adipocytes (11) and macrophages and is present in aortic fatty streak lesions (35) , and the decreased level of TNF-␣ and the observed reduction in lesion size in the SpdϪ/Ϫ mice may be a consequence of reduced macrophage activity and recruitment of monocytes. The atherogenic diet leads to NF-B induction of inflammatory cytokines (22) , and TNF-␣ modulation in SpdϪ/Ϫ mice could be a direct consequence of diet sensitivity.
The consequences of an altered inflammatory marker in atherosclerosis are hard to predict. Lack of IL-6 led to an unexpected acceleration of atherosclerosis (33) , whereas TNF-␣ has been associated with an increased risk for cardiovascular disease in clinical studies (15) . In vitro studies have demonstrated both proatherogenic and antiatherogenic effects of TNF-␣ (6, 27, 32). TNF-␣-deficient mice were not affected (35) , but TNF-␣-deficient apoEϪ/Ϫ mice had 50% reduced lesion areas (3). In contrast, lack of the TNF-␣ receptor p55 accelerated diet-induced atherosclerosis (34) .
Pulmonary phospholipid accumulation and foam cell accumulation is present in SpdϪ/Ϫ mice (17) . The lipid accumulation is suggested to be subjected to a local pulmonaryspecific regulation (9) . The mechanisms of both lipid and inflammatory disturbance in SpdϪ/Ϫ mouse lungs are unknown but can be reversed by the administration of recombinant SP-D (4, 5) . An apparent dual behavior of SP-D (and the similar type of molecule surfactant protein A) in the regulation of inflammation was recently explained by ligand-dependent molecular orientation of the globular lectin domains of the collectins and resulting alterations in receptor binding on the surface of phagocytes leading to reverse NF-B-signaling (10) . Present investigations in our lab are focused on SP-D regulation of inflammation to elucidate further the inflammatory component of atherosclerosis.
